Publicaciones en las que colabora con Francisco Fuentes Jiménez (27)

2024

  1. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  2. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet, Vol. 403, Núm. 10421, pp. 55-66

  3. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis, Vol. 393

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet

  3. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

2021

  1. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  2. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

  3. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

    The Lancet, Vol. 398, Núm. 10312, pp. 1713-1725

  4. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  5. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: The SAFEHEART study

    Public Health Nutrition, Vol. 22, Núm. 8, pp. 1433-1443

  2. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

2018

  1. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study

    Journal of Clinical Lipidology, Vol. 12, Núm. 4, pp. 948-957

2017

  1. Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART

    Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 444-450

  2. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia

    Journal of Clinical Lipidology, Vol. 11, Núm. 1, pp. 260-271

2016

  1. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: Insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study)

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 36, Núm. 9, pp. 2004-2010

  2. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

    Journal of the American Heart Association, Vol. 5, Núm. 9